Company news

Journey Medical Corporation (NASDAQ:DERM) news

Journey Medical Corporation news releases on 6ix. Latest, Sep 8, 2026: Journey Medical Corporation to Participate in September 2026 Investor Conferences

Journey Medical Corporation (NASDAQ:DERM) news

Press releases & updates

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference

Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

Journey Medical Corporation to Participate in October 2025 Investor Conferences

Journey Medical Corporation to Participate in September 2025 Investor Conferences

Journey Medical Corporation to Present at the Emerging Growth Conference

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024